Shares of Wockhardt Ltd are trading flat after touching a day’s high of Rs 1,411.90 on 27th January. This comes despite the firm announcing that its antibiotic Foviscu successfully met the primary endpoint in a phase 3 clinical trial involving patients with complicated urinary tract infections and acute pyelonephritis caused by gram-negative bacteria.

Wockhardt said Foviscu is its fifth proprietary antibiotic to complete a registration-enabling phase 3 study. The other antibiotics are Emrok, Emrok O, Miqnaf and Zaynich.

In a randomised, double-blind phase 3 trial, Foviscu was compared with meropenem. Meropenem is a last-line antibiotic used for severe drug-resistant gram-negative infections.

At the test-of-cure stage, Foviscu achieved a 93.23% clinical cure rate, versus 92.31% for meropenem. It met the primary endpoint with a comparable safety profile.

The company said this is the first phase 3 head-to-head trial of an antibiotic developed specifically for ESBL infections. This trial pits it against meropenem.

According to ICMR data, rising resistance to commonly used antibiotics is forcing higher carbapenem use, accelerating carbapenem resistance.

Wockhardt said Foviscu could reduce dependence on carbapenems, support better antibiotic stewardship, and help curb antimicrobial resistance.

At 3:10 PM, shares of Wockhardt were trading 0.67% lower at Rs 1,342.60 on NSE.

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!